Changing the future of cancer care by accurately predicting patient response to therapies before treatment begins Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and …

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

576 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A Technology Development and Advisory Company Focused on Medical Devices/Biologics Strategic Advisory Services for both large & small medical device/biologics companies including acquisition, licensing, distribution, joint venture agreements Market, Scientific and Clinical Due Diligence Services Business development Services for venture capital, private equity, hedge funds and investment banking clients & their portfolio companies and clients Product/Device development Strategic Product Postioning including licensing, distribtution and market positioning New Company Formation

518 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Targeting diseases at their molecular roots Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.

Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Bioceltix is changing the veterinary therapy standards. We develop innovative biopharmaceuticals based on stem cells. Bioceltix is a biotech start-up which deals with the development of stem cell-based medicinal products for veterinary use. Currently, our main goal is to implement a biopharmaceuticals based on allogenic stem cells. The medicines will be primarily to serve the treatment of accompanying animals. The new product candidates will become a milestone in the field of stem cell-based biopharmaceuticals for veterinary use. As one of the first such Europe-based company, Bioceltix product intends to go through the full registration path to a marketed drugs devised …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

437 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology

77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation at the service of your health and well-being. Pharmaceutical company, R & AMP; D dedicated to the development and marketing of senolytic compounds, food supplements and aging medications, age -related degenerative diseases and cancer.

324 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

281 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Exploiting the conformational complexity of GPCRs to innovate drug discovery Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cell therapy Acceleration and Innovation: Rethinking cell & gene therapy By Institut Curie CellAction (Cell therapy Acceleration and Innovation) is the cell and gene therapy platform of the Paris-Saclay Cancer Cluster (PSCC) at Institut Curie. A first in France, CellAction enables collaborative projects to be launched with industrial partners on a national and international scale. The aim is to accelerate the development of optimized cell and gene therapies. CellAction is founded on the centralization of key expertise required for the drug development process: - Institut Curie's highly qualified medical-scientific teams - Cutting-edge technologies for in vitro and in vivo testing …

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Your genotoxicity R&D partner PrediTox commits to support its clients in evaluating the genotoxic and potentially carcinogenic properties of their compounds. With more than 10 years of expertise in the study of genotoxicity, the PrediTox team will meet your expectations thanks to its innovative technique as soon as possible. Since our assay adapts to any compounds and can be carry out on any type of human cell lines, we are able to offer you personalized studies. Our goal is to provide quality information to our customers to help you in your R&D works or in your various projects, while reducing …

28 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Accelerate drug development for neurological diseases SYNAXYS is French biotech specialized in the characterization of the response of the nervous system for nutraceutic, pharmaceutic and veterinary applications. We offer a complete range of R&D services to support drug development, from defining the dose effects in a human model, to identify biological targets and action mechanism, acute and chronic toxicity, or comparison to established treatments. Our field of application: - Drug positioning - Therapeutic evaluation in a diease model - Neuro-oncology - Data generation for IA modeling Neuro-engineering, Neuronal diseases modeling, Neuro-oncology, Autism, Alzheimer disease, and Glioblastoma

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming science into drug success stories Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible. Translational research, Biotechnology, Pharmaceuticals, …

167 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your partner in uro-genital pre-clinical research UROSPHERE is a leading Contract Research Organization specializing in preclinical urogenital, gastro-intestinal and oncological pharmacology studies. We provide the pharmaceutical and biopharmaceutical industries with a unique experimental research platform combining both in vivo models and in vitro assays on human and animal tissues. Innovation, Uro-genital pathologies, Oncology, PDX models, Organoids, CRO, Preclinical Research, Pharmacology, Drug development, Gastrointestinal pathologies, Experimental models, Pain, and Inflammation

129 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

At Orio Therapeutics, our mission is to save lives by making the regenerative medicine dream accessible and a wide-spread reality. We are dedicated to developing novel regenerative drugs with increased efficacy and reduced side-effects, using cutting-edge targeted drug-delivery technologies to create novel therapeutic proteins. Notably, we strive to demonstrate that efficient drug delivery technologies are not confined to the development of complex devices and drug carriers but can be achieved based on clever molecular designs. We aim to initially validate our program pipeline through the development of a therapeutic molecule for myocardial infarction that has the potential to change the …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Oral small molecules for rare diseases Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package.

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

106 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AI-guided Functional Precision Medicine PreCombTherapeutics AG is a privately held Swiss biotechcompany focused on in vitro cancer diagnostic to improve cancer management. It’s automated microtumor-based 3DTwinTM technology enables clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome. Oncology, Combination therapies, Biotechnology, 3D tissue culture, Precision medicine, Drug profiling, Healthcare, Cancer therapy, Medtech, Life science, AI, and Personalized oncology

132 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

Entreprise de dispositif médical de diagnostic in vitro : Noratest® In vitro diagnostic medical device Diagnostic, Innovation, Maladies neurodégénératives, Alzheimer, Neurosciences, Entreprise, and Entrepreneuriat

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

ATOXIGEN is your partner in early R&D. We offer a variety of standardized or customized assays based on the latest innovations in the fields of cellular biology, molecular biology and genomics. Innovative predictive efficacy assays on reconstructed epidermis or primary cell lines from human explants (proteasome, autophagy, detoxification, anti-ageing...); in vitro genotoxicity testing (micronucleus and chromosome aberration tests); endocrine disruptor screening; customized services. Biotechnologies, Testing & Research, Evaluation toxicologique, and Assurance qualité

89 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Which molecule will stand out INOVOTION is a biotech company which offers you a unique in vivo technology dedicated to anti-cancer treatment evaluations and early toxicity studies. Our Fast, Sensitive, Reliable and Affordable assay will save you time and money, to give you a clear competitive advantage. This breaking-thought technology, based on chick embryo, provides early analysis of your treatments before the classical preclinical stages. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process, increases your R&D productivity and reduces its costs. It’s rapid Go/No Go decision with multi-cancer screening capacities. This next generation of in vivo efficacy …

27 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer

169 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A New Hope for Hemorrhagic Stroke Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North …

33 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

402 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

An innovative drug discovery technology Good morning and welcome, we are pleased to introduce you to our structure. AZELEAD has developed ZebraScreen and ZebraTox, an innovative methodology for rapid and accurate assessment of the efficacy and toxicity of a drug In the past few years, we have seen a lot of attrition in the development of new drugs, with a failure rate of nearly 84% attributed to the low benefit of efficacy / toxicity. Three therapeutic areas are mainly affected by this decrease:  oncology (failure rate of 29.5%),  neurology (failure rate of 14%),  and infectious diseases (failure …

36 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Abzena is the leading end-to-end bioconjugate & complex biologics CDMO+CRO, focused on rapidly moving medicines forward. Abzena is the leading end-to-end bioconjugate, ADC, and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, …

74 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Pioneering inhaled medications for cardiovascular conditions InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route. The lead product under development is an inhaled therapy to treat a common atrial arrhythmia, paroxysmal atrial fibrillation (PAF). Cardiovascular, Inhalation therapy, Biotechnology, Pharmaceuticals, Clinical Development, Drug Formulation, Commercialization, Clinical Research, Pre-Clinical Research, and Regulatory Affairs

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Tackling the toughest cancers. We’re OxSonics, a pioneering clinical-stage therapeutics company committed to developing a ground-breaking platform technology to make anti-cancer drugs smarter, act faster and, above all, work better. Our SonoTran® Platform has been designed to actively enhance the delivery of oncology drugs into solid tumours. SonoTran® is drug agnostic and requires no drug reformulation enabling its use with both existing and novel therapies. We have our own development programs as well as collaborations with Pharmaceutical and biotech companies to work to bring smarter, faster and better therapies to as many patient groups as possible. Drug Delivery, Oncology, Medical …

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology. Drug Discovery, Biotech, Oncology, Fibrosis, Lysosomal Storage Disorders, NASH, and SSc

154 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerare le scoperte, trasformare la vita! Frontage Laboratories is a US-based Contract Research Organization (CRO) that was initially established in New Jersey in April 2001 and later relocated to Pennsylvania in 2004. As an FDA-registered and inspected global pharmaceutical development and manufacturing organization, Frontage is headquartered in Exton, PA, with an impressive network of 26 facilities spread across Pennsylvania, New Jersey, Illinois, Ohio, California, Florida, Canada, Italy, and China. We are dedicated to accelerating the development of innovative therapies by providing a broad range of science-driven and quality-focused services including drug discovery, DMPK, preclinical safety & toxicology, formulation development and …

105 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies. Our team of 300+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer. Our products and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe. The Company considers its employees to be its most valuable asset and we are committed to providing opportunities for individuals to learn and grow as a means to further their professional development. MacroGenics' corporate culture promotes an atmosphere of innovation, open communication and teamwork where employees …

Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Developing precision small molecules to combat hard-to-treat tumors. iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer. oncology, drug development, and clinical development

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative drug substances -

382 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Reliable, reproducible, and scalable 3D in vitro platforms for drug safety & efficacy testing | The Model of ExcellenceTM InSphero is the only 3D in vitro model company with the platform and expertise to modernize drug safety and efficacy testing in a way that empowers researchers to reach their full potential. Our innovative spheroid-based models allow for more effective and safe therapies to get to the clinic faster due to our superior robustness, reliability, reproducibility, and scalability. InSphero’s goal is to help researchers fuel a new era of drug discovery through comprehensive products and services for: - Liver safety - …

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We revolutionize allergy diagnosis ATANIS Biotech AG has developed a novel functional cell based assay that massively simplifies the diagnosis of allergies and can predict treatment success of therapies. This test is used to assess safety and efficacy of potential new drug candidates for allergy treatment. It is being developed for an upcoming commercialization in the clinic. Contact us at: info@atanis-biotech.com Allergy, Diagnostics, In vitro testing, Fee for service, Pre-clinical assessments, Clinical Trials, Food Products, and Allergenicity

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Light Activated Technologies for treating cancers and rare diseases Lightox has developed a new drug for the treatment of early stage oral cancers. The topically applied formulation allows for specific delivery to the lesion and is activated by a specific wavelength of light.

57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

#BeyondInnovation #DermalFiller #CYTOSIAL #AestheticMedicine New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine. Medical Device, Dermatology, Aesthetic, Cosmetic surgery, Regenerative medicine, Ultra-pure chitosan, and Hyaluronic Acid

303 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology

Through conferences, community and market insights, we create partnerships that help advance the next pillar of medicine Phacilitate creates an environment where promising innovation can turn into the products that are changing the future of medicine. Recognised as the market leader in providing the life science sector with strategic insight, inspiration and unparalleled business networking, Phacilitate enables professionals to stay abreast of the issues driving life science innovation. #advancedtherapies #biotech #celltherapy #genetherapy Clinical Development, Cell Therapy, Gene Therapy, Oncology, Cancer, Precision Medicine, Biotech, Advanced Therapy, Biotechnology, and Life Sciences

197 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Centre d'Etudes Biologiques et Pharmaceutiques OUR MISSION: Provide analytical support for all product development phases (human & veterinary medicines + Medical Device) with: Consulting and expertise Formulation development support Analytical method development and validation Stability studies QC testing Veterinary pre-clinical and clinical studies Développement analytique, Etudes de stabilité, Affaires technico-réglementaires, Consulting & expertise, Troubleshooting (pré et post AMM), Etudes précliniques et cliniques vétérinaires, Analytical method development, ICH validation, Stability study, and Quality Control GMP

94 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The Immune system under control Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies

408 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people. Drug Discovery, Molecule characterization, Drug repurposing, and Novel compound applications

285 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

PepKon is a french biotechnology company founded in 2022. The company develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. These drug-candidates come from over a decade of academic research, resulting in seven scientific publications and two patent families

134 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

CRO specialized in pharmaceutical drugability for research Expertise in Human and Animal health solid form characterization and formulation development. We deliver both experimental support and consulting services to biotechnology and pharmaceutical companies, not-for-profit organizations and complementary CROs. We are member of the association AFSSI, 1st French research center in Life Sciences, as a founding member and member of the board of Directors. Since March 2019 Joel Vacus, Drugabilis CEO & CSO, is vice-President of AFSSI. https://www.afssi.fr/ Feel free to contact us in order to exchange about your preclinical drug development! contact@drugabilis.com Lead optimization, Formulation, and Physical form optimization

63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The only company with a suite of systemic and high-throughput in vitro drug discovery solutions FluoSphera S.A. is the only company providing a suite of high-throughput, systemic, in vitro drug discovery solutions. Its proprietary chip-free platform uses flexible 3D cell systems that mimic the complex biology of the human body to rapidly and precisely study human response to systemic drug delivery. FluoSphera offers four distinct drug discovery solutions: (1) multiplexing for target selectivity, (2) measuring systemic efficacy and toxicity, (3) systemic biomarker identification, and (4) translational species optimization.

57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A better future. For everyone. Egualia (formerly Assogenerici) is the Italian Federation of Industries for Accessible Medicines which today represents more than fifty companies, over 95% of the companies producing generic, biosimilar and value-added medicines. Founded in 1993, it is a member of the European association of the sector, Medicines for Europe, and welcomes multinational and Italian companies present throughout the territory, which produce both for the domestic and foreign markets, as well as companies engaged in the production of drugs on behalf of third parties for the entire pharmaceutical industry. Generics and biosimilars cover 80% of therapeutic areas and …

62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Giving Life to Science PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed …

63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Cellvax, founded in 2001, is a preclinical biotech company which provides in vitro and in vivo studies allowing accelera Cellvax, founded in 2001, is a preclinical CRO which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis (OA) fields. Cellvax is a fast-growing technology-driven preclinical service company. Today, Cellvax directly employs and through R&D collaborations motivated and differently skilled scientists and engineers, working in interdisciplinary teams on several innovative products. Preclinical studies CRO, Animal models, Cancer, Osteoarthritis, Bio-markers, …

61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The cosmetic expertise from the ingredient to the finished product Specialized in the assessment of finished cosmetic products, ingredients and cosmetic raw materials, we perform tolerance and efficacy studies. BIO-HC in-vitro : toxicological and pharmacological tests on cell models (primary cells, cell lines) and tissue models (epidermis, skin reconstructed in vitro). In vitro tests, GLP studies, and OECD tests

60 similar entities Type: SMB Activities: biotech deeptech cosmetics Technologies: Synthetic Biology

Galenix, a Key pharmaceutical R&D partner, helps you to reduce your timeline by offering innovative solutions DRUG DELIVERY SOLUTIONS - DRUG PRODUCT DEVELOPMENT - LICENSING-OUT OPPORTUNITIES Galenix provides a range of full R&D pharmaceutical services and Drug Delivery Solutions to health companies for fast access of their products on the market. ●●● From the sourcing of the API through the Drug Product development process, including preformulation, formulation, to clinical supplies, quality control, ICH stabilities and regulatory dossier submission for Europe and US FDA registration. Galenix provides its customers drug products “ready to launch” holding a Marketing Authorization. ●●● Galenix Innovations …

49 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Fast-track your pipeline with preclinical excellence. in vitro & in vivo research services since 1991. At a glimpse ETAP-Lab is a French preclinical CRO with over 30 years' expertise in derisking research & advancing drug development for pharmaceutical and biotech companies. Our expertise covers dermatological, cardiological, neurovascular and neurological diseases thanks to our dedicated research labs. Our range of services • A portfolio of over 60 tried-and-tested in vitro and in vivo reference models. • Proof of concept & pharmacological experiments • Efficacy & safety studies Working with us • Personalized & expert advisory • Tailor-made & flexible study designs …

38 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Development of covalent small molecules to transform the treatment of autoimmune and inflammatory disorders ARTICA Therapeutics and its seasoned team started operatons in 2020 and was supported by pre-Seed financing from BioGeneration Ventures. Artica is dedicated to developing novel small molecule medicines for inflammatory and autoimmune indicatons. Artca is at the forefront of covalent binding technology as well as in label-free cellular-based screening approaches. The unique combinaton of these capabilities allows rapid progression of the best drug candidates that have unprecedented and superior characteristics, creating novel and highly selective therapies for patients with unmet medical need.

21 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

657 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your local champion and alternative partner Newbury Pharmaceuticals was founded in 2020 by Swedish Karl Karlsson. We are rapidly growing and offer a product portfolio of specialty pharma medicines with focus on the Scandinavian markets. The portfolio strategy includes niche and value-added small molecules, products based on peptide technology as well as biosimilars in a variety of therapeutic categories. The portfolio consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology representing more than 70 percent. The company was listed on Nasdaq First North, February 2022.

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

435 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ecrins Therapeutics is a biotechnology company which focuses on the discovery and development of novel anti-cancer compounds from the preclinical phase to phase II clinical proof of concept. In addition to the drug discovery, Ecrins Therapeutics provides a range of products and services for the benefit of our customers in biotechnology companies, universities, public research institutions and in the pharmaceutical industry. The mission of the commercial division of Ecrins Therapeutics is to help medical chemists and drug hunters to discover, characterize and advance their lead compounds through the drug development process. Visit http://ecrins-therapeutics-services.com/ for more information. Our research and production …

44 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Antibody for Therapy AbTx is a preclinical stage biotech company developing the next generation of oncology treatments to treat incurable cancers. AbTx platform is developing mAb innovative enzymatic conjugation. Our platform unlock New Frontiers in Medicine to overcome ADC major drawbacks associated targeting solid tumors by generating antibody Fragment Drug Conjugates (FDCs). ADC, Oncology, and drug develoment

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Tarian Pharma's mission is to develop new drugs that ensure optimized cancer treatment by protecting cancer patients from side effects that would lead to dose reductions or discontinuation. This approach is designed to increase patients' chances of recovery and survival. Tarian Pharma was created by two dermatologists and a pharmacist, with more than 75 years of experience in the pharmaceutical industry and having been actively involved in the development and marketing of more than 15 new drugs in Europe, the United States and Asia.

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle

239 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology

Pioneering science for patient choice Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

85 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovation in medical needs. Inmedical Therapeutics es un fabricante de productos médicos y soluciones en formato hidrogel ubicado en Vitoria. Biotecnología, Endoscopia, Farmacéutica, and Producto Médico

126 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Crafting next generation of small molecule anti-parasitic drugs by harnessing comparative structural data At ASTRA Therapeutics, we are redefining parasite drug development by leveraging the specificity of ParabulinsTM. Our mission is clear: to lead the fight against parasitic diseases with precision-engineered solutions.

505 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Novel small-molecule drugs in immunology, fibrosis and women health Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting indications with high unmet medical need in immunology, fibrosis and women health. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, Inflammation and autoimmune diseases, IP generation, IBD, Ulcerative Colitis, Crohn's disease, Fibrosis, and Uterine fibroids

252 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Design. Formulate. Deliver. ten23 health is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines. Our sites in Visp and Basel 🇨🇭 support our clients in developing differentiated, stable, usable, and safe injectable treatments for patients. More about us: www.ten23.health biopharmaceuticals, pharmaceutical industry, Contract Manufacturing, Sterile Manufacturing, Aseptic Manufacturing, Drug Device Integration, Analytical Development, Analytical Testing, Molecule Selection, Packaging , and Formulation Development

227 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

your partner for preclinical research Biossan : A French CRO dedicated to biomedical research Biossan helps its academic and industrial partners develop their innovations by performing preclinical trials under controlled conditions. Biossan specializes in evaluating medical devices, new techniques, and pharmaceutical products in healthy and pathological models. Conduite et accompagnement de projet de recherche, Organisation de formation, and Bien-être et expérimentation animale

88 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

CNS/PNS - In vitro - In vivo - Drug Development Neuro-Sys is a research-intensive and innovative organisation specialising in pharmacology and in advanced in vitro and in vivo models of neurodegenerative diseases, mode of action research, and drug development in the CNS and PNS fields. We provide pharmacological profiles of lead compounds and explore their underlying mechanism of action and studies to determine the neuroprotective activity. We’re dedicated to providing high-level technical expertise in a collaborative relationship with our clients and accompany you along the drug development stages, from preclinical to clinical. Our expertise: › Alzheimer’s disease (AD) › Parkinson’s …

29 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

15 years of Quantitative Pharmacology Solutions applied to the development of drug candidates. PhinC Development is the PK Modeling & Simulation partner for small to medium sized pharmaceutical or biotech companies, who need to move forward in early drug research. Based on Model-Informed Drug Development, PhinC helps you to increase the confidence in decision making and reduces cycle time of your development. Our mission consists in developing the best models to take advantage of all the research data at every phase (in vitro, in vivo animal and human) and carry out robust simulations and predictions requested and recommended by the …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Creative Technologies for Efficient Therapeutics, Precision medicine Inoviem Scientific is a private Bioanalytical company which delivers enabling information to secure drug discovery programs and to take informed decision by closing the gap between preclinical and clinical development. We reconcile translational pharmacology and human physiology by using fresh patient material from the target cohort, embracing the complexity of human diseases. Inoviem's enabling technologies are working in pathological conditions to get the treatment in development to the right patient. Our indication-agnostic access to patients combined with innovative label-free platforms deliver Target identification and validation, targets & Mode of Action deconvolution, patient stratification, …

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

#Pharmaco-imaging, #nuclear medicine, #PET/MRI, #Radiochemistry, #Preclinical models Created in 2008 in Dijon, Pharm’image is a regional center of excellence in Pharmaco-imaging. Unique in France, it brings together hospitals, biotechnology, and pharmaceutical companies, to offer state-of-the-art of functional and molecular imaging technologies (MRI, PET, SPECT, CT), ranging from small-animal scale for preclinical experimentation to clinical exploitation Its aim is to deploy cutting-edge medical imaging technologies to evaluate biomarkers that can be used to track treatment efficacy and select the active and most promising drug candidates. imaging, preclinical evaluation, pharmacology, molecular imaging, nuclear medicine, radiochemistry, bioconjugation, translational research, in vivo pharmaco-imaging, First …

57 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Exploring together! We support biopharmaceutical research with translational preclinical models. CYNBIOSE is France-based non-clinical research organization. Preclinical CRO, Pharmacokinetics, POC, Efficacy, Immunotherapies, Drug, Early tox, CNS, Infectious diseases, Respiratory diseases, Non clinical, CRO, PK, PD, and TK

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its …

250 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy. Drug development, Biotechnology, Pharmaceuticals, Antibody-drug conjugates, DAR1 ADC, and ADC

155 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nonclinical expert in cardiovascular pharmacology & electrophysiology and vascular functions PhysioStim is a French preclinical CRO dedicated to cardiovascular pharmacology and electrophysiology from discovery stages to clinical development. Whatever the therapeutic areas, we ensure robust and valuable preclinical data on cardiac and vascular activities and secondary pharmacology to secure in-vivo development and bring new safe therapies to patients. Thanks to our predictive and translational models, we define the POC of drug discovery, we investigate secondary pharmacology with on and off-target liabilities, and we address the safety purpose to build and support your IND submission (with mandatory and not mandatory assays). …

39 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Novalix is a premier drug discovery CRO Novalix is a premier drug discovery partner to biotech firms and pharmaceutical companies. We apply our exceptional scientific talent and exclusive resources across our platforms to improve the odds of success at each critical pre-clinical stage. The better the science, the better the outcomes. For additional information visit www.novalix.com Target based drug discovery, NMR, SPR, Epigenetic targets, Nuclear receptors, Protein-ligand co-crystal structures by XRD, Native mass spectrometry, FBDD, Organic Chemistry, cryo-electron microscopy, Chemical development, Medicinal chemistry, Structural Biology, in vitro pharmacology, DNA-encoded libraries, Flow chemistry, Chemical process research, DMPK, and ADME

125 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

198 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

ILC Therapeutics is a specialist UK-based developer of hybrid interferons, a new engineered drug class with improved therapeutic profiles, enabling broad applications across multiple indications. Hybrid interferons combine favourable attributes of specific natural interferon sub-types to produce novel drug candidates designed to deliver reduced toxicity and improved efficacy. ILC Therapeutic’s platform approach has produced two first-in-class lead candidates, AlfacyteTM and DermacyteTM focused on antiviral and dermatological indications respectively, which are progressing towards the clinic.

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients ATMP, Gene Therapy, Biologics, Drug development, Clinical trials, GMP, Growth, H2020, Uppsala, IBD, Wound treatment, Scar, Topical, Oral, Research, Science, Immunology, Immunophysiology, microbiology, Applied microbiology, Regulatory excellence, Skin, Diabetes, Cutting edge, and IBD

229 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating global drug development Cytochroma predict how drugs will react in a global population in health or disease. Our unique, ethnically diverse library of iPSC and automated cell culture generates robust, reliable, mature hepatocytes for toxicity testing. We are supporting life science companies, de-risking safe compounds prior to clinical testing, making new drug development faster, safer and more efficient. toxicity testing, liver specialists, hepatocyte testing, disease models, high throughput, high content screening, iPSC, automated manufacture, machine learning, artificial intelligence, predictive testing, and pre clinical testing

132 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

334 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that are at the forefront of drug discovery and development in oncology and immuno-oncology. Providing a range of integrated solutions, including preclinical research services, translational platforms, and clinical trial support. Its offer includes the world's largest commercially available patient-derived xenograft (PDX) collection and more than 600 tumor organoid models utilizing Hubrecht Organoid Technology, covering 22 cancer indications. Crown Bioscience's expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in …

62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Provider of cells, 3D tissues and testing services. Epithelix Sàrl is a Swiss biotech company specialized in human tissue engineering. Epithelix provides innovative R&D solutions for the study of human respiratory diseases (e.g. Asthma, COPD, Cystic Fibrosis, etc.) and for inhalation toxicity testing of chemicals, while reducing the number of animal experiments. Human pulmonary toxicology, Preclinical Drug Development, and Human Tissue Reconstitution

56 similar entities Type: SMB Activities: biotech deeptech Technologies: 3D Printing Synthetic Biology

Rapid Therapeutic Drug Monitoring Axithra is a spin-off from Ghent University and imec, developing a platform to quickly and accurately measure and monitor drug concentrations in blood, paving the way for treatments tailored to the specific needs of each individual, at any given time. The first application is focusing on personalizing beta-lactam antibiotics treatments in the intensive care unit. The company’s platform is based on proprietary optical and photonics technology and will allow physicians to optimize patient care by enabling personalized treatments.

67 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing cell therapy for inflammatory diseases via neonatal cardiac progenitor cells and their secretomes Revolutionizing cell therapy to address inflammatory diseases driven via neonatal cardiac progenitor cells and their secretomes.

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Taking the guesswork out of drug development At Chromodynamics, we are on a mission to deliver instruments that eliminate guesswork from drug development and prescription. Our unique technology allows for an enormous improvement in speed, efficacy, and cost with which exciting new treatments like immunotherapy are developed. We have been recognised as one of the most promising startups in the Eindhoven Brainport region and are expanding our team to ramp up our product development. Imaging systems, Multispectral imaging, Real-time analysis, Chemical imaging, Spectroscopy, Scientific instruments, Contract research, and Data analysis

249 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

549 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Enhance Quality of Life Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care and provide superior health outcomes. Oral Thin Films, Geriatrics, Paediatrics, Patient autonomy, Equitable Access, Innovative medicines, Medication adherence, Central Nervous System, Women's Health, and Neurology

316 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for …

155 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Dedicated to transforming the lives of patients with rare hematologic diseases and cancers. Forma Therapeutics (Nasdaq: FMTX) is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. We aim to create futures for patients, their families …

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing new treatments to patients faster and more efficiently. Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.

174 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics'​ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery

211 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our expertise, Your discovery Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas. Based at Colwick Quays Business Park, Nottingham UK, our experienced scientific team offers bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Multiplex Immunoassay, Target and biomarker validation, In vitro functional assays, Molecular Biology, Receptor binding, Toxicity testing, Immuno-Oncology, Oncology, Immunology, Inflammation, and Respiratory

380 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

European Mammalian CRDMO - From Discovery mgs to Clinical GMP kgs. Icosagen is a unique European CRDMO, being successfully in the business for more than 25 years as an independent family-owned company. As such, we combine pre-clinical CRO and clinical CDMO development expertise at one single site for therapeutic antibodies, multispecifics, ADCs, and other complex recombinant protein drug candidates. As a CRDMO we discover, develop, and manufacture proteins seamlessly from research concepts into pre-clinical and clinical development stages. This includes everything from small-scale transient productions to stable high producing cell lines, to manufacture clinical GMP materials in our modern 200/1000L …

135 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Creating class-leading ADCs with enhanced tumor specificity Through our highly experienced ADC Research & Development Team, we are building a pipeline of class-leading ADCs with superior therapeutic index (TI) for difficult-to-treat cancers. Our approach is to develop the best ADC for any given target or tumor sub-type rather than 'technology-driven ADCs'. All our ADCs incorporate tumor-selective release & activation of the most relevant payload according to mechanism, optimizing anti-cancer efficacy and enhancing patient safety. Antibody-Drug Conjugates, PermaLink™, Conjugation Chemistry, Cancer research, ADCs, Drug Development, Therapeutics, Antibodies, Toxins, Cancer Treatment, ADC Stability, Antibody Drug Conjugate, Drug Discovery, Biotechnology, Preclinical, Bioconjugation, Organic …

29 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cell therapies. Precigen: Advancing Medicine with PrecisionTM Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

542 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology